TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04785794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.
Study: NCT05848128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Tavilermide ophthalmic solution
Description: Twice a day topicial dosing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: Twice a day topical dosing
Study: NCT04775264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Electric Field Ablation
Description: Catheter ablation of Ganglionated Plexi (GP) structures on the epicardial surface of the heart during cardiothoracic surgery
Study: NCT06003088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653(5mg)
Description: Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653(5mg)
Description: Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653(25mg)
Description: Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653(25mg)
Description: Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
Study: NCT05930184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-wound Transversus Abdominis Plane Block
Description: 0.25% bupivacaine 20ml was injected using no24 needle into a plane between internal oblique muscle and transversus abdominis muscle around every wound 2 cm. from wound opening. The procedure was confirmed by laparoscopic vision and the injection was done before removal of laparoscopic port.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltration
Description: 0.25% bupivacaine 20ml was injected using no24 needle into subcutaneous tissue after the abdominal sheet was sutured.
Study: NCT04869306

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel
Description: After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel + carrier
Description: After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
Study: NCT05689229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
Study: NCT04900714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decremental PEEP
Description: High PEEP to low PEEP.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound score
Description: lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood gas analysis
Description: Blood gas analysis to determine arterial oxygen tension

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Registration of respiratory mechanics
Description: Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
Study: NCT04294836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
Study: NCT04900714

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of dead space
Description: Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
Study: NCT04294836

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: PLACEBO Capsules 500mg
Study: NCT04054050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Bright light (10,000 lux) therapy will be administered via a light box.
Study: NCT04550234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad prolonged release HPMC capsule
Description: Randomized subjects will receive oral dose of verinurad HPMC capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad prolonged release HPMC capsule
Description: Randomized subjects will receive oral dose of verinurad HPMC capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol Tablet
Description: Randomized subjects will receive oral dose of allopurinol tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol Tablet
Description: Randomized subjects will receive oral dose of allopurinol tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad/Allopurinol FDC Capsule
Description: Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad/Allopurinol FDC Capsule
Description: Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad prolonged release gelatin Capsule
Description: Randomized subjects will receive oral dose of Verinurad gelatin capsule.
Study: NCT03949478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
Study: NCT04755907

Intervention type: PROCEDURE
Intervention: surgical resection
Description: Surgical resection will be performed for locoregional lesions or liver metastases.

Intervention type: PROCEDURE
Intervention: surgical resection
Description: Surgical resection will be performed for locoregional lesions or liver metastases.

Intervention type: PROCEDURE
Intervention: surgical resection
Description: Surgical resection will be performed for locoregional lesions or liver metastases.

Intervention type: OTHER
Intervention: adjuvant chemotherapy
Description: Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.

Intervention type: OTHER
Intervention: adjuvant chemotherapy
Description: Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.

Intervention type: OTHER
Intervention: adjuvant chemotherapy
Description: Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.

Intervention type: OTHER
Intervention: neoadjuvant therapy
Description: Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.

Intervention type: OTHER
Intervention: neoadjuvant therapy
Description: Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.
Study: NCT06505863

Intervention type: PROCEDURE
Intervention: Transanal total mesorectal excision
Description: Transanal approach in surgical treatment of rectal cancer along the anatomical and embryological planes, called total mesorectal excision, as described in 1988 by Heald et al.
Study: NCT03923556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
Study: NCT04897347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Trunk-Support-Trainer (TruST)
Description: This will involve tailoring the level of postural assistance via force fields and systematically introduce postural task-progression across training sessions. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static Trunk Support
Description: This will involve static support for the trunk via a trained therapist. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)
Study: NCT06296875

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil
Description: mixed vegetable oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: Krill oil
Study: NCT05689177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)
Description: Booster dose administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)
Description: Booster dose administration
Study: NCT05504135

Intervention type: DIAGNOSTIC_TEST
Intervention: Pharmacogenomics Testing
Description: To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
Study: NCT05193175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping
Study: NCT04759001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor FMT
Description: This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FMT
Description: This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
Study: NCT05878951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intra-detrusor OnabotulinumtoxinA is commonly known as botox
Study: NCT05433116

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib
Description: 20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
Study: NCT05159245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4/6
Study: NCT05455060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal formula (CHF)
Description: Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
Study: NCT05785559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine biopsies
Description: uterine biopsies performed on the areas of cesarean section scars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine biopsies
Description: uterine biopsies performed on the areas of cesarean section scars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine biopsies
Description: uterine biopsies performed on the areas of cesarean section scars
Study: NCT06085014

Intervention type: OTHER
Intervention: Standard of care
Description: All patients will undergo, as clinically indicated, AF ablation by pulmonary vein isolation achievable by radiofrequency, cryoenergy, or electroporation. All patients will preliminarily undergo electroanatomic mapping of the atrium by CARTO/Navx/Rhythmia system indifferently. Patients will be given follow-up visits at 3-6-12 months, during which any arrhythmic recurrences will be assessed
Study: NCT05159245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: MET ex14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: RAF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: MEK1, MEK2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib+Trametinib
Description: RAF, MEK1, MEK2
Study: NCT05964933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Pulpotomy
Description: Complete caries removal and excision of the entire coronal pulp to the level of the root canal orifices will be performed. After haemostasis, the pulp chamber will be filled with Biodentine® and a final direct restoration placed in 1 or 2 visits.~If there is no bleeding from the exposed pulp, pulpectomy and root canal treatment will be performed instead, and the patient will be excluded from the study.
Study: NCT05159245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: FGFR2
Study: NCT05964933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy and Root Canal Treatment
Description: After complete caries removal and pulp exposure, Pulpectomy will be performed to remove all pulp tissues. Conventional root canal treatment will be performed using rotary instrumentation followed by obturation with gutta percha and traditional sealers in 1 or 2 visits. A final restoration will be placed to ensure a good coronal seal, and this may include full coronal coverage restorations if clinically indicated.
Study: NCT06085014

Intervention type: OTHER
Intervention: Data collection
Description: There's no patient involvement. Data of patients who underwent ablative procedures two years before the start of the study will be retrospectively analyzed
Study: NCT04846465

Intervention type: OTHER
Intervention: Screening in picture archiving and communication system (PACS) .
Description: Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.

Intervention type: OTHER
Intervention: Screening in picture archiving and communication system (PACS) .
Description: Screening in picture archiving and communication system (PACS) , the images of the participants who underwent computed tomography (CT) of the femur and acetabulum.
Study: NCT05532605

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac rehabilitation phase I protocols
Description: cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehab phase I protocols + Mindfullness base therapy
Description: cardiac rehab phase I protocols: ankel pumps, limbs ROMs, bed mobility. Do 5-10 minutes daily of breath awareness practice on your own. Plus Mindfullness base therapy
Study: NCT06021509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoClasp® transcatheter mitral valve clip and steerable guide catheter
Description: The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.
Study: NCT06354478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride 0.5 MG/ML
Description: Will be used either alone or in combination of gabapentin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride 0.5 MG/ML
Description: Will be used either alone or in combination of gabapentin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Will be used either alone or in combination of Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Will be used either alone or in combination of Dexmedetomidine
Study: NCT05293236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApTOLL
Description: ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApTOLL
Description: ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApTOLL
Description: ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline for intravenous infusion
Study: NCT04739878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway Ultrasound
Description: Comparison between Airway ultrasound and CT cervical
Study: NCT06137651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgery
Study: NCT05722418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CB-011
Description: CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
Study: NCT06137651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trotabresib
Description: Given PO
Study: NCT05078476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manchester Short Splint
Description: 3-5 days after tendon repair the patient will start with hand therapy and the described protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relative Motion Flexion
Description: 3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
Study: NCT06137651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trotabresib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV
Study: NCT05782738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Use dedicated two stents technique for treatment of coronary bifurcation stenosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Use dedicated two stents technique for treatment of coronary bifurcation stenosis
Study: NCT06428331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB518 for injection
Description: SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.